Investigational drug · Phase 2
Tulmimetostat
Also called: DZR123, Tulmimetostat DL1, Tulmimetostat DL2, Tulmimetostat DL3, Tulmimetostat Doses 1
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Progressive Metastatic Castrate Resistant Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Advanced Solid Tumor.
Phase 2Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
6
Any phase or sponsor naming "Tulmimetostat"
First trial start
2019
Sep 18, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Tulmimetostat", any sponsor or status.
Conditions studied
As listed on its trial records.
- Progressive Metastatic Castrate Resistant Prostate Cancer
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Advanced Solid Tumor
- Diffuse Large B Cell Lymphoma
- Lymphoma, T-Cell
- Mesothelioma, Malignant
- Prostatic Neoplasms, Castration-Resistant
- Endometrial Cancer
- Ovarian Clear Cell Carcinoma
- Metastatic Castration-resistant Prostate Cancer
Approved drugs for the same conditions: Prostate cancer · Endometrial cancer · Oncology · Hematology and blood cancers · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Tulmimetostat" as an intervention, largest first.
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04104776 · 300 participants (planned) · Start Sep 18, 2019 · Primary completion Feb 27, 2030
Drug: Tulmimetostat; Enzalutamide · For: Advanced Solid Tumor; Diffuse Large B Cell Lymphoma; Lymphoma, T-Cell and 5 more
Sites: Tampa, Florida; Atlanta, Georgia; Chicago, Illinois · 80 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07206056 · 188 participants (planned) · Start Oct 15, 2025 · Primary completion Nov 9, 2029
Drug: Tulmimetostat DL1 QD; Tulmimetostat DL2 QD and 7 more · For: Progressive Metastatic Castrate Resistant Prostate Cancer
Sites: Denver, Colorado; Jacksonville, Florida; Atlanta, Georgia · 35 sites in all
- TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07190300 · 181 participants (planned) · Start Jan 13, 2026 · Primary completion Aug 2, 2032
Drug: Tulmimetostat; Darolutamide and 3 more · For: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Sites: Birmingham, Alabama; Iowa City, Iowa; Westwood, Kansas · 31 sites in all
VA Office of Research and DevelopmentFederal agency
NCT05467748 · 66 participants (planned) · Start Dec 8, 2025 · Primary completion Dec 8, 2027
Drug: Tulmimetostat · For: Non Small Cell Lung Cancer
Sites: Long Beach, California; Sacramento, California; San Diego, California · 5 sites in all
Lan CoffmanAcademic, hospital or other
NCT05942300 · 30 participants (planned) · Start Jan 30, 2024 · Primary completion Jul 31, 2028
Drug: CPI-0209; carboplatin · For: Recurrent Ovarian Cancer
Sites: Pittsburgh, Pennsylvania
- Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary SyndromeActive, not recruiting
Washington University School of MedicineAcademic, hospital or other
NCT05944562 · 24 participants · Start Jan 9, 2024 · Primary completion Feb 28, 2027
Drug: Tulmimetostat · For: Mycosis Fungoides; Sezary Syndrome; Mycosis Fungoides/Sezary Syndrome
Sites: St Louis, Missouri
Newest research
PubMed records naming it or its code names, newest first.
- The Role of EZH2 n Malgnant Pleural Mesotheloma and Beyond: Current Practce and Future Perspectves.
Kucukoner M, Demir T, Alsubaie AM, et al. · Curr Oncol Rep 2026
- Polycomb repressive complex 2 (PRC2) pathway's role in cancer cell plasticity and drug resistance.
Goleij P, Heidari MM, Tabari MAK, et al. · Funct Integr Genomics 2025
- Comprehensive Target Engagement by the EZH2 Inhibitor Tulmimetostat Allows for Targeting of ARID1A Mutant Cancers.
Keller PJ, Adams EJ, Wu R, et al. · Cancer Res 2024
Also in development for Progressive Metastatic Castrate Resistant Prostate Cancer
- luxdegalutamideJSB462, ARV-766Phase 24 trials
Novartis · Prostatic Cancer, Castration-Resistant, Progressive Metastatic Castrate Resistant Prostate Cancer, Prostate Cancer Metastatic
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.